Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.

Revenue
+9.13%
EPS
+8.64%
Free cash flow
+15.0%
Total debt
+22.8%

Quarter to September 2026, against a year earlier

693.03 16.09 +2.38%
Market cap
$250.8B
P/E
36.5×
Fwd P/E
35.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

32.61 26.98 26.93 35.55
P/S ratio
4.90 4.05 4.01 5.27
P/FCF ratio
34.47 26.93 25.27 32.71
P/Operating CF
63.19 153.40 87.53 97.95
P/B ratio
4.09 3.52 3.53 4.56
EV/Sales
5.48 4.86 4.77 5.97
EV/EBITDA
23.20 20.52 19.94 24.43
EV/FCF
38.54 32.36 30.04 37.03
Current Ratio
1.89 1.53 1.55 1.81
Net Debt/EBITDA
8.63 14.16 12.09 10.70
Debt/Equity
0.67 0.77 0.74 0.71
Earnings Yield
3.07% 3.71% 3.71% 2.81%
Free Cash Flow Yield
2.90% 3.71% 3.96% 3.06%
Free Cash Flow per Share
8.01 2.22 4.53 5.71
Book value per Share
141.68 139.62 142.01 148.02
Free Cash Flow
3,019.00 825.00 1,679.00 2,114.00
EV/EBIT
31.52 27.83 27.14 33.39
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026